During therapy with an antineoplastic agent, hydroxyurea, early abrupt megaloblastic changes were evident in the marrow. Correlative biochemical studies suggested that the megaloblasto-sis resulted from an abrupt decrease in reductive conversion of ribotide to deoxyribotide and that hydroxyurea induces defective reductive conversion. Evidence for similar changes in the spleen in considerably less, suggesting that splenic hematopoietic mesenchyme may have a DNA biosynthetic pathway that is different from that of the bone marrow.
|Original language||English (US)|
|Number of pages||4|
|State||Published - Jun 1967|
ASJC Scopus subject areas
- Cancer Research